Long-Term Care

Clinical benefits of hallucinogens re-evaluated

Contemporary Long-Term Care Weekly, April 15, 2010

Spurned for years by mainstream medicine following their boisterous display during the 1960s counter-culture movement, doctors are taking a closer look at hallucinogens and the constructive role they may be able to play in treating mental conditions such as addiction, depression, and end-of-life anxiety. Preliminary studies suggest that when administered in a safe and controlled setting, hallucinogens like psilocybin, which is the psychoactive component in some mushrooms, can induce reflective mental states that often lead to lasting positive effects, according to The New York Times.

This week in San Jose, CA, researchers from around the world are meeting for a conference on psychedelic science to discuss hallucinogens and specifically the studies of psilocybin. It’s the largest such conference held in the U.S. in 40 years. While they’re hesitant to make too much of the small-scale studies completed thus far, researchers are encouraged by the early results and are intrigued by the potential for improved treatment of individuals suffering from mental conditions.

Most Popular

Related Articles